Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Address: ul. Domaniewska 49, 02-672 Warszawa
Tel: +48 22 345 93 00
Web: http://www.teva.pl/u235/navi/73
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients. Teva is among the top 15 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.
In Poland we operate together with a Teva group members – Teva Kutno and PLIVA Kraków – a Polish medicines producers with many years of history and experience.
For over 70 years now we have been with Polish doctors, pharmacists and patients. Today, we are a state-of-the-art and dynamically developing pharmaceutical company, offering prescription medicines and OTC products (sold without prescription, over the counter).
We produce and market medicines used in infections, type 2 diabetes, urological diseases, osteoporosis, central nervous system disorders, heart and respiratory diseases, for transplantations and cancer treatment.
Teva’s manufacturing sites in Kutno and Kraków meets highest standards in manufacturing and controlling pharmaceutical products.
Owing to membership in Teva global concern, access to state-of-the-art technologies and research and development works we will keep expanding our offer for doctors and pharmacists with top quality medicines at prices affordable for patients.
Teva’s scope of activity extends to many facets of the industry, with a primary focus on the manufacturing and marketing of products in the following categories:
Human pharmaceuticals
Teva produces generic drugs in all major therapeutics and steriles in a variety of dosage forms, from tablets and capsules to ointments, creams and liquids.
In addition, Teva manufactures innovative drugs in niche markets where it has a relative advantage in research and development.
Active Pharmaceutical Ingredients (API)
Teva competitively distributes its API to manufacturers worldwide as well as supports its own pharmaceutical production. These activities, which comprise the core businesses of the company, account for 90% of Teva’s total sales.
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market,…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here